Netherton Syndrome Market Forecast 2031

The Netherton syndrome market size in 2021 stood at US$ 21.15 million and is projected to reach US$ 106.34 billion by 2031 from US$ XX billion in 2023. The market is expected to register a CAGR of 20.6% in 2023–2031. The increasing number of awareness campaigns, drug launches and robust pipeline are likely to remain key Netherton syndrome market trends.

Netherton Syndrome Market Analysis

Netherton syndrome (NS) is a multisystem genetic disorder illustrated by a triad of clinical manifestations such as congenital ichthyosiform erythroderma, immunodeficiency, and hair shaft abnormalities. Owing to the intricate pathogenesis of the disease, there are currently very few therapies available for patients with NS. The Netherton Syndrome market is witnessing tremendous growth due to increasing awareness of Netherton Syndrome and a growing number of product launches. Furthermore, the growing number of clinical trials and technological developments provide significant opportunities for the future growth of market players. However, the risk of side effects associated with the drugs used to treat Netherton syndrome is hampering the growth of the market.  

Netherton Syndrome Market Overview

Netherton syndrome is a rare genetic disorder indicated by scaly skin, hair shaft abnormalities, and a predisposition to allergic reactions. The Netherton syndrome market has gained significant attention recently due to increased awareness, genetic testing advances, and targeted therapy development. Additionally, a growing interest among pharmaceutical companies and researchers in developing innovative treatments for this rare genetic disorder is driving the market.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Netherton Syndrome Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Netherton Syndrome Market Drivers and Opportunities

Increasing Drug Launches and Robust Pipeline to Favor Market

Various companies around the world are focused on launching and developing new, effective, and innovative therapies for rare diseases. In May 2020, Azitra, Inc. a clinical-stage medical dermatology drug manufacturer received US Food and Drug Administration (FDA) as Rare Pediatric Disease Designation to ATR-12 for the treatment of Netherton syndrome. In July 2020, Sixera Pharma developed a treatment for Netherton syndrome that targets and specifically certain proteases in the skin. In May 2020, Toronto Innovation Acceleration Partners (TIAP), AmorChem II Fund L.P., and Evotec SE invested US$ 1.75 million into a drug development project that emphases on Netherton syndrome that affects one in 200,000 newborns worldwide. Therefore, the increasing emphasis on treatment for Netherton syndrome and development of drug candidates is expected to foster the growth of the market.

Growth in Development of Technologies – An Opportunity for Netherton Syndrome Market Growth

Promising developments have been made in pathogenetic based therapies such as gene and enzyme replacement therapy. Recent insights into the immune profile of ichthyosis patients have also opened new avenues for repurposing biologics. Biological therapy contains a wide range of products, such as monoclonal antibodies that target specific markers, e.g., tumor necrosis factor-alpha (TNF-α), interleukin-13 (IL-13), and interleukin-17 (IL-17). and interleukin-23 (IL-23). There is extensive experience with biologics in inflammatory skin diseases such as atopic dermatitis and psoriasis. In 2021, a new clinical trial was started examining the one-month use of a cream containing SXR1096 in NS patients (NCT05211830). SXR1096 is a powerful inhibitor of KLK7, KLK5, and KLK14. Twenty NS patients participated in the phase I/II study for evaluating safety and efficacy compared to placebo. The majority of the players concentrate on developing markets, such as India, Australia, China, Saudi Arabia, and UAE, owing to presence of patients suffering from rare diseases in these countries and increasing need for clinical assistance and awareness regarding treatment options. Therefore, the growing need for new therapies creates growth opportunities for market players.

Netherton Syndrome Market Report Segmentation Analysis

Key segments that contributed to the derivation of the Netherton syndrome market analysis are therapy.

• Based on therapy, the Netherton syndrome market is divided into keratolytic agents, biological therapy, oral and topical steroids and retinoids, topical calcineurin inhibitors, and radiation therapy. The keratolytic agents segment held the largest share of the market in 2023, and the same segment is anticipated to register the highest CAGR during the forecast period.

Netherton Syndrome Market Share Analysis by Geography

The geographic scope of the Netherton syndrome market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South America/South & Central America.

North America has dominated the Netherton syndrome market. The growth of the market in North America is attributed to the prevalence of Netherton syndrome in the region. Netherton syndrome (NS) incidence in the United States is 1 to 2 cases per 200,000 live births. NS has a poor prognosis and significant mortality in the first years of life due to potentially fatal complications. Market players are focusing on drug development for Netherton syndrome in order to deal with significant prevalence. In April 2020, LifeMax Laboratories, Inc. received fast track designation for its pipeline candidate LM-30 for the treatment of Netherton syndrome from FDA. In April 2023, US-based Quoin Pharmaceuticals recruited a pediatric population for its ongoing Phase II/III study evaluating QRX003 in Netherton syndrome (NS). QRX003 is a broad-spectrum serine protease inhibitor that downregulates skin kallikrein hyperactivity.

Netherton Syndrome Market Regional Insights

The regional trends and factors influencing the Netherton Syndrome Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Netherton Syndrome Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Netherton Syndrome Market Report Scope

Market Players Density: Understanding Its Impact on Business Dynamics

The Netherton Syndrome Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Netherton Syndrome Market are:

1. Lifemax Laboratories, Inc.
2. Azitra, Inc.
3. Sixera Pharma Ab
4. Dermelix Biotherapeutics
5. Matrisys Bioscience
6. Quoin Pharmaceuticals Ltd.

Disclaimer: The companies listed above are not ranked in any particular order.

Netherton Syndrome Market News and Recent Developments

The Netherton syndrome market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. The following is a list of developments in the market for Netherton syndrome:

• MatriSys BioScience, a private, clinical-stage pharmaceutical company focused on developing live biotherapeutic products (LBPs) for chronic dermatologic indications provided updates on MSB-2040 used in Netherton’s syndrome receiving regulatory applications (orphan designation in US and EU; IND and CTA) and plans to initiate Phase 1 study in patients in H2 23. (MatriSys BioScience, News, 2023)
• BioCryst Pharmaceuticals, Inc. announced updates from its drug discovery process and additional therapies from its pipeline that the company will highlight at a Research and Development (R&D). BCX17725 is a potent and selective investigational fusion protein KLK5 inhibitor designed to provide best-in-class, potentially disease-modifying treatment for people with Netherton syndrome. The company looks ahead to begin clinical trials of BCX17725 in 2024. (BioCryst Pharmaceuticals, Inc., Press Release, 2023)
• National Institute of Health (NIH) awarded ResVita Bio US$ 250,000 Phase 1 SBIR grant to develop RVB-001 as a treatment for Netherton syndrome. (ResVita Bio, News, 2022)
• ResVita Bio, a cellular therapies startup, announced that the FDA granted Rare Pediatric Disease Designation to RVB-001 for treating Netherton Syndrome. RVB-001 is a genetically engineered probiotic that is topically applied to temporarily colonize the skin and continuously release LEKTI, thereby inhibiting proteolysis and restoring the integrity of the epidermal barrier. (ResVita Bio, News, 2022)

Netherton Syndrome Market Report Coverage and Deliverables

The “Netherton SyndromeMarket Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:

• Market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Market dynamics such as drivers, restraints, and key opportunities
• Key future trends
• Detailed PEST/Porter’s Five Forces and SWOT analysis
• Global and regional market analysis covering key market trends, major players, regulations, and recent market developments
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments
• Detailed company profiles